Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Study links bone density with breast cancer risk:

This article was originally published in Clinica

Executive Summary

Bone mineral density (BMD) is one of the most powerful predictors of breast cancer, especially advanced breast cancer, among the elderly, suggests a US study of nearly 9,000 women. Older women with high BMD are nearly three times as likely to develop the disease as are those with low BMD, researchers from the University of Pittsburgh Graduate School of Public Health report in the Journal of the National Cancer Institute (June 20). The investigators stress that high BMD is not the cause of the disease, but rather a marker for hormone levels.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT071737

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel